Genomewide association studies have implicated the CLEC16A gene in several autoimmune diseases, including multiple sclerosis (MS) and type 1 diabetes. However, the most associated single-nucleotide polymorphism (SNP) varies, and causal variants are still to be defined. In MS, two SNPs in partial linkage disequilibrium with each other, rs6498169 and rs12708716, have been validated at genomewide significance level. To explore the CLEC16A association in MS in more detail, we genotyped 57 SNPs in 807 Norwegian MS patients and 1027 Norwegian controls. Six highly associated SNPs emerged and were then replicated in two large independent sample sets (Norwegian and British), together including 1153 MS trios, 2308 MS patients and 4044 healthy controls. In combined analyses, SNP rs12708716 gave the strongest association signal in MS (P ¼ 5.3 Â 10
Introduction
Genomewide association studies (GWAS) have demonstrated that single-nucleotide polymorphisms (SNPs) in the C-type lectin domain family 16, member A (CLEC16A) gene at chromosome 16p13, influence susceptibility in both multiple sclerosis (MS) and type 1 diabetes (T1D). [1] [2] [3] Multiple replication and candidate gene studies have verified this region as being disease associated in T1D and MS, and association with CLEC16A has also been found in anti-cyclic citrullinated peptide (CCP) negative rheumatoid arthritis, juvenile idiopathic arthritis, Addison's disease and NOD2-negative Crohn's disease. [4] [5] [6] [7] [8] [9] The association of CLEC16A SNPs across multiple immune-mediated diseases and the observation that the gene is almost uniquely expressed on immune cells, make a common effect on autoimmunity likely. The CLEC16A protein belongs to the C-type lectin family whose immune functions include differentiation of self versus non-self glycoproteins and the induction of the appropriate immune response. 10 CLE-C16A is an atypical C-type lectin carrying only a short Ctype lectin domain unable to bind carbohydrates, and the function of the protein is still unknown. 9 Limited data exists on CLEC16A isoforms, and despite its considerable length spanning 200 000 bp, only three transcripts are annotated at the University of California Santa Cruz (UCSC) Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly (http://genome.ucsc.edu). All the strongest SNP associations found so far are situated in seemingly noncoding regions, and their biological consequences are largely unknown.
The original CLEC16A SNP association in MS, found by the International MS Genetics Consortium (IMSGC) GWAS in 2007, was rs6498169 in intron 22 . 2 This SNP association has been replicated and confirmed at genomewide significance level in MS (Po5 Â 10 À7 ). 6, 11 In T1D, the strongest association so far has been found for four SNPs situated in intron 19 and 22; rs12708716, 9 rs725613, rs2903692 and rs17673553, 1 which are all in fairly strong linkage disequilibrium (LD) (r 2 ¼ 0.66-1.00; haploview v 4.1, hapmap release 21, CEU sample set (Utah residents with Northern and Western European ancestry from the Centre de'Etude du Polymorphism Human (CEPH) collection). 12, 13 The LD between the MSassociated rs6498169 and the T1D SNPs is modest (r 2 ¼ 0.18-0.26), 12, 13 and association with rs6498169 has not been found in T1D. 8, 14 In contrast, the T1D-associated SNPs rs12708716 and rs725613 have indeed also shown strong association with MS in an IMSGC study including more than 2000 trio families, 5000 cases and 10 000 unrelated controls (P ¼ 1.6 Â 10
À15
), and in a Sardinian study (P ¼ 6.4 Â 10 À5 ), respectively. 4, 15 The reported CLEC16A SNP associations also vary for other autoimmune diseases. The originally described MSassociated SNP rs6498169 has been shown to be associated with anti-CCP-negative rheumatoid arthritis and juvenile idiopathic arthritis, but not anti-CCP-positive rheumatoid arthritis, Addison's disease and NOD2-negative Crohn's disease. 5, 8, 16 Vice versa the T1D SNPs rs2903692 and rs12708716 have shown association with NOD2-negative Crohn's and Addison's disease, respectively. 5, 8 Thus to date, MS is the only disease described to be associated with both rs6498169 and the LD block containing the four T1D associated SNPs. The only fine-mapping study of CLEC16A performed in MS so far is an Australian study (n ¼ 1146 cases and n ¼ 1309 controls) of several MS risk genes, where 44 tagging SNPs in the CLEC16A gene pointed towards rs6498169, the most significantly associated CLEC16A SNP in the original IMSGC GWAS. 2, 17 It does not appear from the paper whether rs12708716 was tested in this study.
In order to further explore the CLEC16A SNP association in MS, we conducted fine mapping in two phases, screening a 57 SNP panel in a Norwegian MS patientcontrol sample set in the first phase and replicating the top hit findings in two large independent Norwegian and British sample sets in the second phase. Furthermore, we studied the expression levels of different CLEC16A transcripts in thymus and blood in order to correlate these with the genotyping results.
Results

Screening phase
Our screening phase comprised a 57 SNP panel specifically designed to (i) explore SNPs in LD with the MS-associated rs12708716, (ii) test SNPs previously reported in autoimmune disease and (iii) tag the entire CLEC16A gene. The panel was genotyped in a Norwegian sample set, which after removal of three individuals with more than 50% missing genotypes, included 804 MS cases and 1027 controls. Five of 57 markers failed in the screening phase: rs794423 and rs12927773 did not genotype because of assay failure, whereas rs45537935, rs7204935 and rs3177383 were genotyped as monomorphic. Genotype success rates were above 95% for all remaining markers, and all SNPs were in Hardy-Weinberg Equilibrium (P40.001) in patients and controls. Association results and inclusion criteria for all SNPs in the screening phase can be found in Supplementary Table 1 .
Five markers were associated with a Po0.001 in the screening phase (Table 1 ). All were included in the study as part of the tagging SNP set, except rs6498169, previously reported to be associated with MS and anti-CCP-negative rheumatoid arthritis. 2, 6, 8, 11 The most significantly associated SNP, rs12923849 has previously showed some degree of association with T1D. 1 The other three top hits in our screening phase; rs9934231, rs6498168 and rs7206912 have not previously been reported to be associated in MS or other autoimmune diseases. Because of failure of genotyping rs6498168 in the replication phase, it was replaced by a SNP in complete LD (r 2 ¼ 1), rs8060411, and this SNP was for completeness, also tested in the screening panel.
Neither the MS-associated rs12708716 (P ¼ 0.006) nor any of the SNPs selected on the basis of LD with this variant (that is, r 2 40.6) were among these top hits. However, several of them showed significant association in the screening (Po0.01) (Supplementary Table 1 ). As the magnitude of their association was negligibly different from rs12708716, we chose to only include the already confirmed associated SNP rs12708716 in our replication.
To evaluate the correlation of the six SNPs chosen for replication, we looked at their LD pattern in the screening sample set (Supplementary Figure 1) The measurements of deviation from the HWE are given for controls only.
b SNP rs8060411 was typed in the screening sample set as a replacement for SNP rs6498168, assay of which failed in the replication phase. Table 2 . In the Norwegian replication sample set, all SNPs except rs12923849 were replicated to be associated at the 5% significance level, with rs7296012 being the most strongly associated (P ¼ 2.3 Â 10
À4
). In the UK replication sample set, only rs12708716 (P ¼ 4.5 Â 10
) and rs12923849 (P ¼ 0.015) were significantly associated in the trios and case controls combined. The association with rs12708716 had previously been found for the entire UK sample set in an IMSGC study. 4 However, for all the other SNPs included in the replication, the trends of association in the British samples were in the same direction as for the two Norwegian sample sets.
Combining the screening and replication data including genotypes of 1113 trios, 3102 MS patients and 5047 controls (Table 2 ) collected in Norway and the UK, the strongest association was seen for SNP rs12708716
À7
, odds ratio ¼ 1.18, 95% confidence intervals ¼ 1.11-1.25), which correlates with earlier reports in MS and T1D. 4, 9 The other SNPs also reached highly significant P-values on their own, including SNP rs7206912, not previously demonstrated to be disease associated (P ¼ 3.4 Â 10
, odds ratio ¼ 1.14, 95% confidence intervals ¼ 1.08-1.21). Significant population heterogeneity (Po0.05) was seen for all SNPs except the most associated rs12708716, and to adjust for this all combined analyses were calculated with nationality as confounder.
LD, haplotype and logistic regression calculations
The correlation between the most significantly associated SNP rs12708716 and the other five replicated top hit SNPs was modest (r 2 o0.4; Figure 1a ), but LD at the D 0 level was high (D 0 40.65; Figure 1b) . The relationship between the six top hit SNPs was therefore further explored by haplotype analyses (Table 3) , which interestingly showed that only six haplotypes were commonly seen (45%) in the tested populations. Among these six haplotypes there was only one significant risk haplotype carrying all the risk alleles of the six replicated SNPs, and one highly associated protective haplotype harbouring all the protective alleles. One other haplotype identical for all SNPs except carrying the risk allele of SNP rs12923849, showed a protective effect (P ¼ 0.02), which would speak against this SNP being a causal variant. Among the not significantly associated haplotypes, were haplotypes that carry either the risk or protective allele for rs12708716 and rs9934231. They were also seen to always carry all nonrisk alleles of the three SNPs mapping to one LD block; rs7260912, rs806411 and rs6498169. Lastly, we performed logistic regression analyses on all top hit SNPs to further explore the dependency of these SNP associations. The other five top hit SNPs lost their significant association when conditioning on rs12708716, whereas rs12708716 remained highly significant when conditioning on the other top hit SNPs (Table 4 ). These data suggest that rs12708716 is the best candidate for being the causal variant in MS.
Expression analyses
We analysed CLEC16A RNA expression in 42 thymic tissue samples, and in 24 peripheral whole-blood homozygotes for the risk allele (peripheral blood n ¼ 14, thymus n ¼ 17) and carriers of the protective allele (peripheral blood n ¼ 8, thymus n ¼ 21). The rationale for this division was to increase statistical power as few thymus samples (n ¼ 6) and no blood samples were homozygotes for the protective allele. No association with rs12708716 genotype was found looking at the expression levels of the assay comprising all isoforms nor for the short and long isoform separately. However, we found that the relative expression of the short and long isoform was significantly associated with rs12708716 genotype in the thymus samples (P ¼ 0.004), where a higher relative proportion of the shorter isoform versus the long isoform was found for the individuals harbouring the risk genotype AA. As we compared the relative C T s of the two isoform assays directly and not through a standard curve, we cannot tell whether this relationship is because of an increase in the short isoform or a decrease in the long isoform. The same relationship was not found for the peripheral blood samples (P ¼ 0.76) (Figure 2 ).
Discussion
The results of our fine-mapping analysis of CLEC16A in a large sample set including 1113 MS trios, 3102 MS patients and 5047 healthy controls from Norway and the UK, indicated that the strongest CLEC16A SNP association in MS was the previously reported MS-associated SNP rs12708716. Association at the other SNPs tested seemed to be related to LD with rs12708716, with the risk allele from each of the other SNPs occurring on the same haplotype as the risk allele of rs12708716. Logistic regression showed that rs12708716 withstood conditioning on the five other top hit SNPs. Likewise the other SNPs lost significance conditioning on rs12708716.
Altogether, among the SNPs tested the MS-associated SNP rs12708716 appeared to exert the superior association.
Haplotype analysis and LD-D 0 showed that there had been little historical recombination on the main haplo- Haplotype minor frequency threshold is set to 5%. The P-values account for population heterogeneity and are calculated by setting nationality to confounder. All P-values are noncorrected for mulitple testing. Exploring the CLEC16A gene in MS I-L Mero et al type carrying the rs12708716 risk allele. However, the r 2 was relatively low because of frequency differences between the associated alleles, providing sufficient power to demonstrate primary association to rs12708716 by logistic regression analyses. The rs12708716 SNP and the four other SNPs comprising the risk haplotype identified in our study are non-coding SNPs located in intron 10, 19, 20 and 22. Among these, rs12708716 is the best candidate for being the causal variant even though we cannot rule out variants in strong LD with this SNP. Interestingly, Todd and colleagues have performed extensive sequencing on the CLEC16A gene region, and found neither non-synonymous or rare variants within the gene, nor any variant in the neighbouring genes that overcome the association of the CLEC16A SNP rs12708716 in T1D.
9,18
Both up-and downstream of the CLEC16A gene are other interesting candidate genes for autoimmune disease, including the MHC2 transcription factor CIITA and the cytokine signalling suppressor SOCS1 gene (http://genome.ucsc.edu/). However, CLEC16A lies within its own LD block, and little D 0 LD is seen with these two candidate genes on either side (www.hapmap. org). Thus, the disease association signal picked up by GWAS is likely to come from the CLEC16A gene itself. In our screening panel, we genotyped one SNP downstream of SOCS1, rs243329 (P ¼ 0.03), which has been found associated with T1D, and one SNP in CIITA, rs8048002 (P ¼ 0.71), which has shown association with Addison's disease. 7, 9 Both SNPs should based on low LD (D 0 o0.35, r 2 o0.1), be independent of the CLEC16A-associated SNPs found in MS (see Supplementary Figure  1) . Still, evidence of a role for SOCS1 and CIITA in MS is emerging. Recently, Zuvich et al. 19 published a study showing association of a polymorphism in the SOCS1 gene associated in MS. Another study by Bronson et al. 20 showed association between MS susceptibility and variation in CIITA in patients with the MS predisposing HLA-DRB1*1501 allele. Even if these associations are apparently independent of CLEC16A because of very limited LD between the associated polymorphisms in either gene, 19, 20 polymorphisms within the CLEC16A gene could potentially affect expression levels of SOCS1 or CIITA, or vice versa. Thus, a role of all three genes in MS should be further investigated.
To date, only limited expression data on CLEC16A has been published. CLEC16A encodes a suggested immune receptor, and shows association with multiple autoimmune diseases. This could mean that mutations in the gene cause a general autoimmune dysfunction. As the thymus is relevant for the establishment of central tolerance, it is relevant to study the expression of CLEC16A in thymic tissue. We found association between rs12708716 genotype and the relative expression of a short (21 exons) and long (24 exons) CLEC16A transcript in thymus. In addition to fewer exons (lacks exon [22] [23] [24] , the short transcript contains a 48 bp deletion not found in the long transcript comprising the exon 10-11 boundary (http://genome.ucsc.edu). rs12708716 is The y-axis represents (C T mean short isoform/C T mean long isoform). C T is inversely related to quantity, thus, there is a higher relative proportion of the short isoform in thymus samples with the risk genotype AA compared with AG and GG.
No peripheral blood samples harboured the rarest genotype GG. P-values were calculated by Mann-Whitney U-test.
situated in intron 19, whereas rs9934231, rs8060411, rs7206912 and rs6498169, which are also on the described MS-associated haplotype are in intron 10, 20 or 22. Thus, they cluster in some proximity to regions where differences are seen in the transcripts. Hakonarson et al. 1 have previously studied CLEC16A expression in NK cells in view of the T1D-associated SNP rs2903692 and found that homozygotes for the A allele showed a trend towards increased CLEC16A mRNA expression (KIAA0350/CLEC16A Affymetrix probe set 231221 (Affymetrix, Santa Clara, CA, USA) ). Interestingly, this SNP rs2903692 is in strong LD (r 2 ¼ 0.88) with rs12708716. We saw no such direct relationship with genotype and expression level of CLEC16A transcript neither in thymus nor whole blood, nor did we find any effect on relative isoform expression in whole blood as seen in the thymus samples. Of note, thymus samples consist mainly of thymocytes, whereas peripheral wholeblood samples are very heterogenous in cellular composition. It is possible that with more detailed analysis of CLEC16A expression in subsets of white blood cells, the same relationship between CLEC16A transcripts and genotypes would be observed. Our results could therefore speak for thymus-specific and or cell-specific regulatory effect on splicing mechanisms being picked up by rs12708716.
In conclusion, in the most extensive fine-mapping study of the CLEC16A gene in MS performed to date, we find a significant association between MS susceptibility and rs12708716. Furthermore, the rs12708716 genotype is associated with the relative expression of CLEC16A transcripts in thymus, but not in whole blood, suggesting thymus-specific splicing regulation being involved in the expression of this plausible immune receptor gene.
Materials and methods
Subjects
The Norwegian patient sample sets were gathered in the Oslo MS registry and biobank (n ¼ 619) and the Norwegian MS registry and biobank (n ¼ 1394), and were sampled in Oslo with surrounding areas and nationwide, respectively. In the screening phase, we genotyped 807 Norwegian MS patients from the Oslo-and the Norwegian MS registry and biobank, and 1027 healthy controls from the Norwegian bone marrow registry. Of these, 644 patients and 1023 controls had previously been genotyped for rs12708716 in an IMSGC study. 4 Norwegian replication samples consisted of 1206 MS patients from the Norwegian MS registry and biobank, and 2064 Norwegian blood donors as healthy controls. Additionally, 22 duplicates were genotyped within the screening phase and 245 duplicates were typed in both the screening phase and replication phase for quality control.
The British replication sample set consisted of 1153 trios, 1102 UK MS cases, 1980 controls from the 1958 British birth cohort (www.b58cgene.sgul.ac.uk) and 277 duplicates. The whole UK sample set had previously been genotyped for rs12708716 as part of an IMSGC study, 4 whereas 1350 of the patients and all UK controls had been included in the IMSGC GWAS in 2007, thereby being genotyped for rs6498169. 2 All patients included in the study were diagnosed according to Poser and/or McDonald criteria. 21, 22 Demographic information of the patient sample sets is given in Table 5 . In the expression analyses, we used peripheral whole blood samples from healthy bone marrow donors, and thymic tissue samples obtained from 42 Norwegian children under the age of 13 undergoing corrective cardiac surgery at Rikshospitalet. Whole blood was collected on Tempus tubes (Applied Biosystems, Foster city, CA, USA), and thymic tissue samples were collected in RNAlater solution (Ambion, Austin, TX, USA) immediately during surgery. Informed consent was achieved from all participants or their parents (for the thymus samples), and the study was approved by the appropriate local ethical authorities.
SNP panel design and genotyping
The SNP selection for the initial screening phase was done in three stages. The majority of the screening samples (644 cases and 1023 controls) had previously showed nominally significant association with rs12708716 (P ¼ 0.005) in an IMSGC study. 4 We therefore chose to further explore putative associations represented by this known associated SNP rs12708716, and selected a panel of SNPs in moderate-to-strong LD with rs12708716 (r 2 40.6, MAF40.01). We then used a tagging approach among these SNPs to remove redundant SNPs in almost complete LD (r 2 40.95). This left us with 14 SNPs representing 59 SNPs in moderate LD with the reference SNP rs12708716. Second, we incorporated these 14 SNPs by force inclusion into a general mapping panel of the gene (r 2 4 ¼ 0.8 and MAF40.05, capturing 241 SNPs). In this general map, we also forced to include SNPs of particular interest, like possible splice site SNPs or SNPs reported to be associated with other autoimmune disease, including rs6498169. As the CLEC16A gene is fairly contained within its own LD block, making the previously reported CLEC16A association signals likely to originate from genetic variant(s) within the gene itself (www.hapmap.org), we confined our SNP selection area to either end of the longest flanking distance of the CLEC16A gene chr16p13:10945-11184 kb. (dbSNP build 129 SNP track for the Human March 2006 assembly (http://genome.ucsc.edu/). Finally, we added SNPs of special interest from the neighbourhood genes SOCS1 and CIITA or the intergenic region separating these genes. The inclusion criterion for each SNP included in the screening panel is given in Supplementary Table 1. For the SNP selection, we used the Tagger programme 23 incorporated in Haploview v 4.1, 12 and SNP Replication genotyping of our five top hits from the screening phase, along with the already described associated SNP rs12708716 was performed by TaqMan technology. (Applied Biosystems). As the TaqMan assay did not work for one of the top hit SNP (rs6498168), we replaced this SNP with one in complete LD (r 2 ¼ 1; rs8060411), which was then genotyped in both the screening cohort and the replication cohorts. A total of 1029 Norwegian blood donors were previously genotyped for rs12708716 by Skinningsrud et al. 7, 8 For the 1958 birth controls, SNPs rs9934231, rs12708716, rs6498169 and rs12923849, had already been genotyped by the Wellcome Trust Case-Control Consortium and, hence, their genotypes were obtained through the Wellcome Trust Case-Control Consortium website (www.wtccc.org.uk). Further, SNP rs12708716 has previously been genotyped in the complete UK cohort .and does not represent new data. 4 
Expression analyses
Whole-blood RNA from healthy Norwegian bone marrow donors was isolated using the Tempus spin RNA kit and included a DNAse digestion step by AbsoluteRNA Wash Solution (Applied Biosystems). Complementary DNA was produced by the reverse transcriptase kit provided by Eurogentec (Eurogentec, Liege Science Park, Seraing, Belgium). Thymus RNA isolation was performed with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols from whole tissue biopsies from human thymi. The complementary DNA synthesis was performed on total RNA by employing SuperScrip III reverse transcriptase (Invitrogen, Cat. No: 18080-051) and random hexamers with B1000 ng input of total RNA. DNAse digestion was performed with DNaseI (RNase-free) M0303S (BioLabs New England, Ipswich, MA, USA).
An assay comprising known CLEC16A RNA transcripts, and differential expression of short isoform BC112897 (21 exons) and full-length peptide NM_015226.1/AB002348.3 (24 exons) were measured by real-time PCR on an ABI7900HT system using predesigned gene expression assays available from Applied Biosystems. All assays had primers covering exon-exon transition to avoid DNA contamination. B-Rajii RNA was isolated using the RNeasy Mini Kit by Quiagen Inc. (Valencia, CA, USA) and used as positive control for the two isoforms. Expression of the two transcripts in B-Rajii cells was before the real-time experiment confirmed by PCR and gel electrophoresis. RNase P was used as endogenous control/house keeping gene and corrected for when looking at either transcripts alone. Triplicates were used for all samples included in the experiment. Where one replicate was clearly an outlier, this was omitted to leave a comparison of the two closest replicates. C T standard deviation cut off was set to 0.1. As the sample input for the measurement of longand short isoform were the same, C T mean was measured directly and not through RNase P.
Statistical analyses
The data quality control including PED CHECK of the trio samples, genotype success rates and Hardy-Weinberg Equilibrium was performed in Plink v 1.06. 24 Haploview v 4.1 was used for LD plot analyses. 12 Association testing, conditional logistic regression analyses and haplotype analyses were carried out in Unphased v 3.1.4. 25 Haplotype frequency threshold was set to 5%. In the combined analyses, we found significant heterogeneity for several SNPs between the UK and Norwegian population. This was corrected for in all the combined analyses, by setting nationality as confounder. Two of the SNPs (rs12708716 and rs6498169) on the identified MS susceptibility haplotype have previously been confirmed associated with MS at genomewide significance level, and our primary goal for combined data analyses was to single out a primary association. Hence, the P-values are presented noncorrected in the combined material. The comparison of CLEC16A expression and genotype was done by comparing the C T mean distribution among the homozygotes for the risk allele versus heterozygotes and noncarriers for the risk allele by Mann-Whitney U-test performed in GraphPad. Prism v. 5.01 (GraphPad Software Inc., San Diego, CA, USA). from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research
